14 postdoc-in-distributed-systems-and-controls PhD positions at Heidelberg University in Germany
Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
About the Position: The successful candidate will join the project group of PD Dr. Axel Mogk, renowned for his work on bacterial protein quality control systems. The hexameric AAA+ proteins ClpG and
-
PhD position (f/m/d) “How to regulate the duration of mitosis and control cell fate decisions” Centre for Molecular Biology (ZMBH) Heidelberg University, Germany We are seeking highly motivated PhD
-
“Mitochondrial RNA modification- driven metabolic plasticity in leukemic stem cells and drug resistance“ we are looking for a PhD student. The project is is part of the SFB/CRC 1709 “Cellular Plasticity in Myeloid
-
xenograft (PDX) models. To this end, the candidate will have direct access to cutting-edge mass spectrometry and advanced bioinformatics infrastructure. The project is part of the collaborative research
-
“Multi-modal proteomics to understand and overcome niche-related adaptive drug-resistance mechanisms in FLT3-mutated AML“ we are looking for a PhD student. The project is is part of the SFB/CRC 1709
-
“Functional and molecular characterization of AI-based morphological predictors of therapy response in Acute Myeloid Leukemia“ we are looking for a PhD student. The project is is part of the SFB/CRC 1709
-
Heidelberg University is a comprehensive university with a strong focus on research and international standards. With around 31,300 students and 8,400 employees, including numerous top researchers
-
The research group of Prof. Dr. Michael Mastalerz at the Institute of Organic Chemistry, Heidelberg University is seeking the following temporary position from October 15th 2025 or later: PhD
-
Stellenanzeige teilen wanted for the next possible date at the Department of Pediatric Oncology, Hematology and Immunology . Osteosarcoma (OS) is an aggressive bone cancer mainly affecting children and young
-
against cardiac diseases. It is based on extensive preliminary work by our working group, which has demonstrated therapeutic effects of the synthetic peptide in chronic and acute heart failure animal models